temperature excursion was 51.5 fahrenheit total time of excursion was 45 minutes with no AE; Initial information received on 24-Nov-2021 regarding an unsolicited valid non-serious case received from an other health professional.  This case is linked to case 2021SA399637(CLUSTER).  This case involves an unknown age and unknown gender patient for whom it was reported "temperature excursion was 51.5 Fahrenheit total time of excursion was 45 minutes  while receiving vaccines INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT], INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE], DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL], DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT [TENIVAC], MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA], HIB (PRP/T) VACCINE [ACT-HIB], DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE [QUADRACEL], DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE [PENTACEL (VERO)], DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [DAPTACEL] and IPV (VERO) [IPOL] and while treated with TUBERCULIN TEST [TUBERSOL] (product storage error)".  The patient medical history, medical treatment(s), vaccination(s), concomitant medication, and family history were not provided.   On an unknown date, the patient started taking therapy of TUBERSOL (TUBERCULIN TEST) Solution for injection dosage unknown (with an unknown batch number) for tuberculin test.  On an unknown date, the patient received a dose of suspect IPV (VERO) [lot T1D482M and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect DIPHTHERIA-15/TETANUS/5 AC PERTUSSIS VACCINE [lot number and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE [lot number and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/IPV (MRC5) VACCINE [lot number not reported and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect HIB (PRP/T) VACCINE [lot number not and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [lot number and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT [lot number and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [lot number and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [lot number and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B VACCINE [prefilled syringes,  lot number and expiry date: not reported] via an unknown route in unknown administration site for prophylactic vaccination.  It was case of actual medication error due to product storage error [Latency: on the same day].   It was reported "temperature excursion occurred because the refrigerator door was left ajar".  At the time of report no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.